The General Data Protection Regulation (GDPR) is the EU’s core law governing how organizations collect, use, store, and share personal data. It sets strict rules on transparency, consent, data minimization, security, and individuals’ rights.
In force since 25 May 2018, GDPR applies to any organization operating in the EU or processing data of EU residents making it directly relevant to every pharma company engaging with HCPs, patients, or digital channels across Europe.
What is the GDPR?
GDPR applies to:
- Any organization operating in the EU
- Any organization outside the EU that processes data of EU residents
- All personal data, including HCP data, patient data, CRM data, and digital engagement data
It came into force on 25 May 2018.
Why GDPR matters for pharma:
01
HCP data is personal data
Even professional contact details like email, phone, specialty, prescribing behavior are protected under GDPR. Pharma must justify every processing activity with a lawful basis, typically consent or legitimate interest, depending on the country.
02
Consent becomes a strategic asset
GDPR requires consent to be freely given, specific, informed, unambiguous, documented, and revocable at any time. Without valid consent, most digital engagement is not allowed, affecting email marketing, rep-triggered emails, remote detailing, event registration, preference centers, CRM enrichment, and cross-channel orchestration.
03
Profiling and targeting are tightly controlled
Pharma frequently uses segmentation, behavioral analytics, channel preference modeling, and content personalization. Under GDPR, these count as profiling, requiring transparency, a lawful basis, the ability for HCPs to object, and strict data minimization.
04
Patient programs and RWE require heightened safeguards
Health data is special category data under GDPR, requiring explicit consent, strong security controls, clear purpose limitation, and minimal data collection. This affects patient support programs, adherence apps, wearable integrations, real-world evidence studies, and clinical trial recruitment.
05
Vendors and platforms must be GDPR-compliant
Pharma companies must ensure Data Processing Agreements (DPAs), sub-processor transparency, data transfer safeguards (especially outside the EU), and full auditability, covering CRM platforms, marketing automation tools, consent management systems, analytics providers, and omnichannel orchestration platforms.
06
Fines and
reputational risk
GDPR introduced significant penalties: up to €20M or 4% of global annual turnover, plus reputational damage, loss of trust, and operational disruption.
GDPR and
HCP Consent in pharma
This is where many teams get confused. Here is the clean, operational rule set.
✔ Single opt-in is acceptable for HCPs, provided:
- Consent is explicit
- Consent is documented
- Consent is granular
- Consent is revocable
Single opt-in
A user gives consent once, for example by ticking a box or submitting a form. Allowed in most EU countries for HCP email marketing, event invitations, remote detailing outreach, and preference center updates.
✔ Use single opt-in when:
- HCP identity is already verified (e.g. CRM, rep interaction, event registration)
- Local law does not require double opt-in
- The communication is scientific/medical and non-promotional
Double opt-in
A user gives consent twice, by confirming via email. Required or recommended in some countries, Germany and Austria, for email, newsletter subscriptions, and any communication that could be considered commercial.
✔ Use double opt-in when:
- Operating in Germany or Austria
- Running high-risk promotional campaigns
- Consent is collected digitally without identity verification
- You want strong auditability for regulators
GDPR implementation by EU country
Germany 🇩🇪
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Double opt-in | Legitimate interest | Double opt-in |
Key local rules & notes
Art. L34-5 CPCE requires prior consent for promotional email. Legitimate interest may be invoked for promotional comms to HCPs at their professional address where content is directly relevant to their specialty, subject to CNIL guidance. Bloctel opt-out list applies to calls. *Contested basis, requires documented balancing test. Regulator: ANSM, DPA: CNIL
Austria 🇦🇹
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Double opt-in | Legitimate interest | Double opt-in |
Key local rules & notes
DPA opinion requires double opt-in for all marketing. ECG §107 prohibits unsolicited email. National opt-out list (ECG list) must be checked. Soft opt-in permitted for existing customers only. Regulator: DSB, check ECG opt-out list before any outreach
Switzerland 🇨🇭
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Not EU but mirrors GDPR via nFADP (2023). EDÖB recommends double opt-in. Swissmedic enforces HCP promotional rules. Google CMP requirements apply from July 2024. Regulator: EDÖB / Swissmedic, nFADP not GDPR applies.
France 🇫🇷
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest* | Opt-in required |
Key local rules & notes
Art. L34-5 CPCE requires prior consent for promotional email. Legitimate interest may be invoked for promotional comms to HCPs at their professional address where content is directly relevant to their specialty, subject to CNIL guidance. Bloctel opt-out list applies to calls. *Contested basis, requires documented balancing test. Regulator: ANSM, DPA: CNIL
Netherlands 🇳🇱
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Telecom Act Art. 11.7 requires prior consent for e-marketing. Generic addresses (info@) exempt. Soft opt-in for existing relationships. Bel-Me-Niet register for calls. CBG regulates HCP promotion. Regulator: CBG, DPA: AP
Belgium 🇧🇪
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Informed consent required. Generic addresses and existing customers exempt. Soft opt-in permitted for similar products/services. DNCM list must be checked. Unsubscribe link mandatory. DPA: GBA/APD
Spain 🇪🇸
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
LSSI Art. 21 prohibits unsolicited promotional email. AEPD requires reject button at first layer of consent banners. Robinson list for marketing opt-out. AEMPS regulates HCP promotion. Regulator: AEMPS, DPA: AEPD
Italy 🇮🇹
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
D.Lgs. 196/2003 + GDPR apply. Garante enforces actively. Legitimate interest can apply for B2B/HCP comms if strictly role-relevant. Granular consent per channel required. AIFA regulates HCP promotion. Regulator: AIFA, DPA: Garante
Portugal 🇵🇹
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Law 41/2004 implements ePrivacy. Soft opt-in allowed for existing relationships. Generic addresses exempt. No consent required for non-promotional regulatory comms to HCPs. Regulator: INFARMED, DPA: CNPD
Sweden 🇸🇪
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Marketing Act + Electronic Communications Act. Soft opt-in for existing customers. Professional-role emails may be sent without consent if clearly job-relevant. NIX-register for opt-out calls. Regulator: Läkemedelsverket, DPA: IMY
Denmark 🇩🇰
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Marketing Practices Act §10 governs e-marketing. Soft opt-in for similar products to existing contacts. Generic/business addresses exempt. DKMA applies EFPIA code locally. Regulator: DKMA, DPA: Datatilsynet
Finland 🇫🇮
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Act on Electronic Communications Services Ch. 24 governs. Soft opt-in for existing relationships. No consent for non-promotional HCP comms. Fimea regulates pharma promotions. Regulator: Fimea, DPA: Tietosuojavaltuutettu
Norway 🇳🇴
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Not EU but EEA, GDPR applies via EEA Agreement. Datatilsynet recommends double opt-in. Marketing Control Act §15 covers electronic marketing. Reservasjonsregisteret for opt-out calls. Regulator: Statens legemiddelverk, DPA: Datatilsynet
Poland 🇵🇱
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Act on electronic services + GDPR. Prior consent required before cold email or call. No soft opt-in exception for HCPs. Consent must be explicit and documented. Regulator: URPL, DPA: UODO
Czech Republic 🇨🇿
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
AIFP dispensation: if an HCP signs an agreement with AIFP including a data processing clause, no separate consent is needed for spend data. Otherwise standard GDPR consent applies. Regulator: SÚKL, DPA: ÚOOÚ
Hungary 🇭🇺
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
HCO consent required in addition to HCP consent for some spend disclosures. Eht (Electronic Communications Act) governs. OGYÉI regulates pharma promotions. Regulator: OGYÉI, DPA: NAIH
Romania 🇷🇴
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
No specific HCP consent required for spend disclosure (aggregate reporting used). Standard GDPR applies to digital marketing consent. Soft opt-in permitted for existing contacts. Regulator: ANMDM, DPA: ANSPDCP
Greece 🇬🇷
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Hellenic DPA recommends double opt-in. Law 3471/2006 implements ePrivacy. HCO consent also required for spend disclosures. EOF regulates HCP promotions. Regulator: EOF, DPA: HDPA
Luxembourg 🇱🇺
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
CNPD recommends double opt-in for verifiable consent. Law of 30 May 2005 implements ePrivacy. HCO consent required for some spend disclosures. Regulator: Division de la pharmacie, DPA: CNPD
Turkey 🇹🇷
Promotional email to HCP | Non-promotional comms | SMS / messaging |
| Opt-in required | Legitimate interest | Opt-in required |
Key local rules & notes
Governed by KVKK (Law No. 6698, 2016). Explicit prior consent mandatory for all promotional electronic communications. İYS national consent management system, all commercial senders must register HCP consents. Non-promotional and scientific comms may rely on legitimate interest where content is role-relevant. Regulator: TİTCK, DPA: KVKK Kurumu
ePrivacy: what it is and why it matters for pharma
When people refer to “ePrivacy” in the EU, they mean the legal framework that protects the confidentiality of electronic communications and regulates tracking technologies such as cookies, pixels, and device identifiers. Adopted in 2002 and amended in 2009, it is also known as the “Cookie Law” and is implemented differently in each EU member state.
What it covers:
- Cookies and tracking technologies
- Metadata (traffic data, location data)
- Confidentiality of communications (email, SMS, calls, messaging apps)
- Direct marketing rules (email, SMS, automated calls)
- Requirements for consent before storing or accessing information on a device
Pharma operates in one of the most sensitive digital ecosystems. ePrivacy directly affects omnichannel engagement, consent strategy, analytics, and HCP targeting.
01
Cookie consent determines what data you can collect
Pharma websites, portals, and campaigns rely on analytics, retargeting, personalization, channel preference tracking, and HCP journey mapping. Under ePrivacy, none of this is allowed without prior consent, except strictly necessary cookies. This means no analytics, no retargeting, and no cross-site tracking without consent. This is foundational for compliant omnichannel orchestration.
02
Email and digital marketing rules come from ePrivacy
The directive governs when you can send promotional emails, when opt-in is required, and when soft opt-in is allowed (which varies by country). For pharma, this affects rep-triggered emails, approved email, event invitations, remote detailing outreach, and consent capture workflows.
03
HCP communication channels fall under confidentiality rules
ePrivacy protects email content, messaging apps, web conferencing tools, and any electronic communication. Pharma must ensure secure channels, no unauthorized monitoring, proper vendor contracts, and clear transparency to HCPs. This is especially relevant for remote detailing, medical information exchanges, and multichannel follow-ups.
04
Metadata is protected
Metadata covers who contacted whom, when, from where, and using which device, and is confidential under ePrivacy. Pharma platforms that process clickstream data, engagement timestamps, channel usage patterns, or device identifiers require consent or strict safeguards.
05
ePrivacy + GDPR = the full compliance picture
Topic | GDPR | ePrivacy |
| Focus | Personal data | Electronic communications and tracking |
| Covers | CRM, HCP data, patient data | Cookies, pixels, metadata, messaging |
| Consent | One lawful basis among several | Often mandatory before tracking |
| Impact on pharma | Data governance | Digital engagement and omnichannel |
GDPR enforcement:
what are the risks for pharma?
GDPR is actively enforced across Europe, with regulators increasingly targeting sectors that handle sensitive personal data at scale. Pharma is firmly in that category.
The fines
GDPR introduced two tiers of penalties:
- Up to €10M or 2% of global annual turnover for procedural violations (e.g. insufficient records, failure to appoint a DPO)
- Up to €20M or 4% of global annual turnover for substantive violations (e.g. unlawful processing, invalid consent, data transfers)
What regulators look for in pharma specifically
- Invalid or undocumented HCP consent
- Missing or incomplete Data Processing Agreements with vendors
- Unlawful data transfers outside the EU (e.g. to US-based CRM or analytics platforms)
- Failure to honour opt-out requests in a timely manner
- Inadequate security measures around special category data (patient data, health data)
- No appointed Data Protection Officer (DPO) where required
Brand impact of
not processing HCP data
according to consent
01
Loss of HCP trust the most immediate brand impact
When a company ignores that consent:
- HCPs feel their professional boundaries are violated
- They unsubscribe more aggressively
- They avoid digital channels from that company
- Field teams lose credibility (“your company keeps emailing me even though I opted out”)
This directly erodes the brand’s relationship capital with prescribers.
02
Reduced ability to engage consent is a prerequisite for omnichannel
If consent is missing or outdated:
- Email marketing stops
- Rep-triggered emails stop
- Remote detailing becomes restricted
- Event invitations cannot be sent
- Preference centers cannot be used
- CRM enrichment and orchestration break down
This means the brand loses reach, frequency, and channel diversity all core drivers of brand performance.
03
Reputational damage regulators explicitly warn about this
Brand impact includes:
- HCPs discussing non‑compliance in professional circles
- Medical societies questioning the company’s governance
- Negative perception among KOLs and advisory boards
- Internal teams losing confidence in data quality
In pharma, reputation is a strategic asset ,and consent violations undermine it.
04
Public regulatory exposure which becomes a brand story
When a pharma company is fined for consent violations:
- It becomes public
- It is picked up by trade media
- Competitors use it in procurement and tender discussions
- HCPs become more cautious with data sharing
This creates long term brand drag.
05
Internal brand damage operational chaos becomes visible externally
When these issues surface:
- Field teams lose trust in CRM data
- Medical and compliance teams become risk‑averse
- Marketing loses agility
- Leadership sees omnichannel as “too risky”
This slows down brand innovation and reduces competitiveness.
Curious what we can do for you?
How OptInsight helps pharma stay GDPR-compliant
- Personal data control at the level of individual HCPs
- Detailed, real time capturing of opt-ins/opt-outs according to mandatory GDPR Data Processing Record and local regulations
- Single point of truth for HCP data leading to higher data quality and less internal discussions about validity of the collected e-consent
- Data quality algorithm by Match & Merge to reduce duplication & improve golden records
- Seamless connections with your marketing channels (e.g web, e-detail, portal) and automated synchronized with all channels onnected, resulting in no more manual labor plus less mistakes
- Automated synchronization with widely used applications in pharma, such as Veeva & OCE
- Consent & preference center for HCPs
- Data insights based on internal and external resources
Not sure where to start with GDPR-compliant HCP consent collection?
OptInsight is the
e-consent management
platform for pharma & life sciences
The most important
privacy laws
are:
European Union 🇪🇺
The General Data Protection Regulation (GDPR) is a regulation of the European Union (EU) that became effective on May 25, 2018.
United States 🇺🇸
In the United States there are several privacy laws and regulations on a national, state and local level. There is not one national privacy law in the United States. Certain states, like California, introduced their own comprehensive privacy laws and other states are expected to follow.
Canada 🇨🇦
The Personal Information Protection and Electronic Documents Act (PIPEDA) is a federal privacy law that came into effect on January 1, 2004.
Australia 🇦🇺
The Privacy Act 1988 is a federal privacy law that sets standards for the collection, storage, use, and disclosure of personal information by Australian government agencies and some private sector organizations.
Japan 🇯🇵
The Act on the Protection of Personal Information (APPI) is a privacy law that came into effect on May 30, 2017.
Brazil 🇧🇷
The General Data Protection Law (Lei Geral de Proteção de Dados, or LGPD) is a privacy law that came into effect on August 16, 2020.
India 🇮🇳
The Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011 (also known as the IT Rules) is a privacy and data protection law in India.
China 🇨🇳
China has several laws and regulations that relate to privacy and data protection, including the Cybersecurity Law of the People’s Republic of China, which came into effect on June 1, 2017, and the Personal Information Protection Law, which is still in draft form.
Africa
Privacy laws vary by country, with some having comprehensive privacy legislation and others having limited provisions.
Middle East
Privacy laws vary by country, but generally, they follow Islamic principles and are based on personal privacy rights outlined in the national constitution.
Russia 🇷🇺
The privacy law in Russia is regulated by the Federal Law No. 152-FZ “On Personal Data”. It outlines the rules for collecting, processing, and storing personal data.
Switzerland 🇨🇭
Switzerland is implementing new legislation to better protect its citizens’ data. Swiss companies will have to comply with this legislation from September 1, 2023.
Frequently Asked Questions
about GDPR Europe
What are the main privacy laws in the European Union?
The two core privacy laws in the EU are the General Data Protection Regulation (GDPR) and the ePrivacy Directive. GDPR governs how organizations collect, store, and use personal data, including HCP and patient data. The ePrivacy Directive covers electronic communications, cookies, tracking technologies, and direct marketing rules. Together they form the complete compliance framework for any organization engaging with people digitally in Europe, including pharmaceutical companies running omnichannel HCP engagement programs.
What is the name of the European Union's privacy legislation?
The EU’s primary privacy legislation is the General Data Protection Regulation, commonly known as GDPR (Regulation (EU) 2016/679). It came into force on 25 May 2018 and replaced the 1995 Data Protection Directive. Alongside GDPR, the ePrivacy Directive (2002/58/EC, amended in 2009) governs electronic communications and direct marketing across EU member states.
What are the data privacy laws in Europe for pharma companies?
Pharma companies operating in Europe must comply with two main frameworks. GDPR applies to all processing of personal data, including HCP contact details, patient data, CRM data, and digital engagement data. The ePrivacy Directive governs direct marketing communications, cookie consent, and electronic channel rules. Beyond these EU-wide laws, individual member states have additional rules, for example Germany requires double opt-in for all promotional email under §7 UWG, and France has specific rules under Art. L34-5 CPCE. A country-by-country overview is available on this page.
Launching in Europe with synchronized omnichannel consent
Launching in Europe with synchronized omnichannel consent
GDPR for pharma: A practical framework for HCP data
GDPR for pharma: A practical framework for HCP data
GDPR for biotech: Engaging HCPs with consent in Europe
GDPR for biotech: Engaging HCPs with consent in Europe
